646 related articles for article (PubMed ID: 16371020)
21. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
Davies JK; Koh MB; Lowdell MW
Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
[TBL] [Abstract][Full Text] [Related]
22. The allogeneic graft-versus-cancer effect.
Ringdén O; Karlsson H; Olsson R; Omazic B; Uhlin M
Br J Haematol; 2009 Dec; 147(5):614-33. PubMed ID: 19735262
[TBL] [Abstract][Full Text] [Related]
23. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
Wu BY; Guo KY; Song CY; Yang ; Li D
Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
[TBL] [Abstract][Full Text] [Related]
24. Kappa immunoglobulin light chain polymorphisms and survival after allogeneic transplantation for B-cell malignancies: a potential graft-vs-leukaemia target.
Etto TL; Stewart LA; Muirhead J; Bailey M; Schwarer AP
Tissue Antigens; 2007 Jan; 69(1):56-61. PubMed ID: 17212708
[TBL] [Abstract][Full Text] [Related]
25. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
[TBL] [Abstract][Full Text] [Related]
26. Enhanced cytotoxicity of IFN-gamma-producing CD4+ cytotoxic T lymphocytes specific for T. gondii-infected human melanoma cells.
Yang TH; Aosai F; Norose K; Ueda M; Yano A
J Immunol; 1995 Jan; 154(1):290-8. PubMed ID: 7995948
[TBL] [Abstract][Full Text] [Related]
27. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
28. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
29. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL.
Dolstra H; Fredrix H; Preijers F; Goulmy E; Figdor CG; de Witte TM; van de Wiel-van Kemenade E
J Immunol; 1997 Jan; 158(2):560-5. PubMed ID: 8992968
[TBL] [Abstract][Full Text] [Related]
30. Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
Gaschet J; Mahé B; Milpied N; Devilder MC; Dréno B; Bignon JD; Davodeau F; Hallet MM; Bonneville M; Vié H
J Clin Invest; 1993 Jan; 91(1):12-20. PubMed ID: 8423212
[TBL] [Abstract][Full Text] [Related]
31. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone.
Eljaafari A; Yuruker O; Ferrand C; Farre A; Addey C; Tartelin ML; Thomas X; Tiberghien P; Simpson E; Rigal D; Scott D
J Immunol; 2013 Jan; 190(1):184-94. PubMed ID: 23225889
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Fowler DH; Odom J; Steinberg SM; Chow CK; Foley J; Kogan Y; Hou J; Gea-Banacloche J; Sportes C; Pavletic S; Leitman S; Read EJ; Carter C; Kolstad A; Fox R; Beatty GL; Vonderheide RH; Levine BL; June CH; Gress RE; Bishop MR
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1150-60. PubMed ID: 17085308
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
34. Allorecognition of HLA-DR and -DQ transfectants by human CD45RA and CD45R0 CD4 T cells: repertoire analysis and activation requirements.
Merkenschlager M; Ikeda H; Wilkinson D; Beverly PC; Trowsdale J; Fisher AG; Altmann DM
Eur J Immunol; 1991 Jan; 21(1):79-88. PubMed ID: 1671359
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
[TBL] [Abstract][Full Text] [Related]
36. Generation of HLA-A2 subtype specific cytotoxic T lymphocytes from cord blood used for cord blood stem cell transplantation.
Yazaki M; Takahashi T; Ito Y; Ito T; Mori C; Wada Y
Bone Marrow Transplant; 2000 Aug; 26(4):451-3. PubMed ID: 10982294
[TBL] [Abstract][Full Text] [Related]
37. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes.
Yazaki M; Takahashi T; Andho M; Akatsuka Y; Ito T; Miyake Y; Ito Y; Nakamura S; Wada Y
Bone Marrow Transplant; 1999 Jul; 24(2):129-37. PubMed ID: 10455340
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
[TBL] [Abstract][Full Text] [Related]
39. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
